Gambacorti-Passerini C
Division of Experimental Oncology D, Istituto Nazionale Tumori, Milan, Italy.
Int J Clin Lab Res. 1993;23(4):186-91. doi: 10.1007/BF02592307.
Fusion proteins are generated in some solid tumors and hematological neoplasias by inter- or intrachromosome translocations. These proteins are believed to play a causal role in the pathogenesis of these diseases. Fusion proteins, therefore, can be considered tumor-specific/transformation-related molecules. The targeting of such structures could lead in the future to significant progress in the therapeutic index of anti-cancer treatment, by allowing the selective destruction of neoplastic cells. In this article, the author reviews the different oncogenic fusion molecules so far known, the mechanism(s) by which they are generated and the available information regarding their immunogenicity, and analyzes their potential use as future targets for a specific immune response.
在一些实体瘤和血液系统肿瘤中,由于染色体间或染色体内易位会产生融合蛋白。这些蛋白被认为在这些疾病的发病机制中起因果作用。因此,融合蛋白可被视为肿瘤特异性/与转化相关的分子。通过选择性地破坏肿瘤细胞,靶向这类结构未来可能会在抗癌治疗的治疗指数方面取得重大进展。在本文中,作者综述了目前已知的不同致癌融合分子、它们的产生机制以及有关其免疫原性的现有信息,并分析了它们作为未来特异性免疫反应靶点的潜在用途。